Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ADC Therapeutics SA
< Previous
1
2
3
Next >
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 11, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
June 09, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
May 11, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
May 09, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
May 02, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
March 15, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
February 28, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
February 21, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
February 02, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in February Investor Conferences
February 01, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
January 03, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
December 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
December 19, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 07, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
November 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
November 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
October 31, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
September 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.